drugset
drugset / Trial / NCT05632809

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

NCT05632809 ↗

Phase 2 Recruiting 39 enrolled M.D. Anderson Cancer Center Nektar Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.

Timeline

Start
2023-01-10
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NKTR-255 Protein / enzyme biologic — Intravenous
Background Durvalumab Monoclonal antibody — Intravenous

Indications

lung cancer